Back to Authors

Jonasch, Eric W.

0000-0003-0943-2806

Mayo Clinic

The University of Texas MD Anderson Cancer Center

Citations 11

Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma
Koh, Mei Yee , Nguyen, Vuvi, Lemos, Robert, Darnay, Bryant G., Kiriakova, Galina M., Abdelmelek, Mena, Ho, Thai H. , Monzon, Federico A. , Powis, Garth , Karam, Jose Antonio , Jonasch, Eric W. , Ho, Thai , Koh, Mei Yee

Cancer Research | November 24, 2014 | Volume: 75 | Issue: 2 | Pages: 316-329

10.1158/0008-5472.can-13-2190 Get It

Abstract Clear-cell renal cell cancer (CRCC) is initiated typically by loss of the tumor-suppressor VHL, driving constitutive activation of hypoxia-inducible factor-1 (HIF1) and HIF2. However, whereas HIF1 has a tumor-suppressor role, HIF2 plays a distinct role in driving CRCC. In this study, we show that the HIF1α E3 ligase hypoxia-associated factor (HAF) complexes with HIF2α at DNA to promote HIF2-dependent transcription through a mechanism relying upon HAF SUMOylation. HAF SUMOylation was induced by hypoxia, whereas HAF-mediated HIF1α degradation was SUMOylation independent. HAF overexpression in mice increased CRCC growth and metastasis. Clinically, HAF overexpression was associated with poor prognosis. Taken together, our results show that HAF is a specific mediator of HIF2 activation that is critical for CRCC development and morbidity. Cancer Res; 75(2); 316–29. ©2014 AACR.